Modafinil: Adult Dosing, Contraindications, and Adverse Effects
Recommended Adult Dosing
Modafinil is dosed at 200–400 mg once daily, taken in the morning, for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. 1, 2
Dosing Strategies by Indication
- Narcolepsy and Idiopathic Hypersomnia: Start with 200 mg once daily in the morning; may increase to 400 mg daily based on response. 1, 3, 4
- Split-Dosing for Late-Day Sleepiness: For patients experiencing residual late-afternoon sleepiness despite morning dosing, a split regimen of 400 mg at 7 AM plus 200 mg at noon (total 600 mg daily) is more effective than 400 mg once daily. 5
- Obstructive Sleep Apnea: 200–400 mg once daily as an adjunct to continuous positive airway pressure (CPAP); CPAP must be continued as modafinil does not treat the underlying airway obstruction. 2, 6
- Shift Work Sleep Disorder: 200 mg taken approximately 1 hour before the start of the work shift. 7
Special Populations
- Elderly patients: Reduce dose due to decreased clearance. 2, 6
- Hepatic impairment: Reduce dose by 50% in patients with severe hepatic disease. 2, 6
- Renal impairment: Use caution in severe renal insufficiency due to accumulation of modafinil acid metabolite. 6
Contraindications and Precautions
Absolute Contraindications
- History of left ventricular hypertrophy or mitral valve prolapse with prior mitral valve prolapse syndrome when taking CNS stimulants (including ischemic ECG changes, chest pain, or arrhythmia). 2
- Moderate to severe hypertension (uncontrolled). 8
- Known hypersensitivity to modafinil or armodafinil, including prior serious rash, Stevens-Johnson syndrome, angioedema, anaphylaxis, or multi-organ hypersensitivity reactions. 2
Serious Warnings Requiring Caution
- Pregnancy: Modafinil may cause fetal harm based on animal data; a 2018 pregnancy registry report showed higher rates of major congenital anomalies in children exposed in utero. 1, 3, 4
- Oral contraceptive interaction: Modafinil reduces the effectiveness of hormonal contraceptives via enzyme induction; alternative or additional contraceptive methods are required. 1, 8
- Cardiovascular disease: In a Canadian trial, a 35-year-old obese narcoleptic male with prior syncope experienced a 9-second asystolic episode after 27 days of modafinil 300 mg/day. Increased monitoring of heart rate and blood pressure is appropriate; a retrospective analysis showed 2.4% of modafinil-treated patients required new or increased antihypertensive medications versus 0.7% on placebo. 2
- Recent myocardial infarction or unstable angina: Consider increased cardiovascular monitoring. 2
Abuse Potential
- Modafinil is a Schedule IV controlled substance with potential for abuse or dependency, though actual abuse cases are rare and it has lower abuse potential than amphetamines or methylphenidate. 1, 6, 8
Common Adverse Effects
Most Frequent Adverse Events (≥5% and More Common Than Placebo)
The most common adverse effects in placebo-controlled trials were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia. 2
Condition-Specific Adverse Event Profiles
- Narcolepsy patients: Significantly elevated risks of diarrhea (RR 2.16) and nausea (RR 2.44) compared to placebo. 9
- Obstructive sleep apnea patients: Higher risks of insomnia (RR 5.82), anxiety/nervousness (RR 3.26), and headache (RR 1.92). 9
- Shift work sleep disorder patients: Elevated risks of insomnia (RR 4.09), anxiety/nervousness (RR 3.85), and nausea (RR 2.93). 9
Dose-Dependent Effects
- Headache and anxiety are dose-related adverse effects, increasing with doses of 200,300, and 400 mg/day. 2
Discontinuation Rates
- In clinical trials, 8% of modafinil-treated patients discontinued due to adverse events versus 3% on placebo; the most frequent reasons were headache (2%), nausea, anxiety, dizziness, insomnia, chest pain, and nervousness (each <1%). 2
Laboratory Abnormalities
- Mean plasma levels of gamma-glutamyltransferase (GGT) and alkaline phosphatase (AP) were elevated following modafinil administration, though few patients had values outside the normal range. 2
Serious but Rare Adverse Events
- Stevens-Johnson syndrome, angioedema, anaphylaxis, and multi-organ hypersensitivity reactions have been reported. 2
- Psychiatric symptoms including mania, delusions, hallucinations, and suicidal ideation may occur, particularly in patients with pre-existing psychiatric disorders. 2
Clinical Pearls and Pitfalls
Long-Term Tolerability
- Modafinil is well tolerated long-term with no evidence of tolerance developing during 40 weeks of treatment; disease severity remained "much improved" or "very much improved" in 58% of narcolepsy patients at 40 weeks. 10
- No withdrawal phenomena (fatigue, vivid dreams, insomnia, hypersomnia) occur after treatment cessation, unlike amphetamines. 8, 10
Drug Interactions
- Modafinil induces and inhibits several cytochrome P450 isoenzymes (particularly CYP3A4 and CYP2C19), creating potential for interactions with drugs from all classes. 6, 8
- Monitor patients on warfarin, cyclosporine, or other narrow therapeutic index drugs metabolized by these pathways. 6
Limitations
- Modafinil does not suppress cataplexy in narcolepsy patients; separate anticataplectic therapy (e.g., sodium oxybate, venlafaxine, clomipramine) is required for this symptom. 1, 6, 8, 11
- Does not replace CPAP in obstructive sleep apnea; continued use of CPAP is essential. 6